Balaji Prasad
Stock Analyst at Barclays
(3.51)
# 904
Out of 5,139 analysts
147
Total ratings
49.19%
Success rate
5.29%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $5.20 | +380.77% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $13.41 | -17.97% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $19.16 | +25.26% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $12.86 | -30.02% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $169.41 | +18.06% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $24.53 | -22.54% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $71.14 | -15.66% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $124.65 | +95.75% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $8.76 | +173.97% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $41.01 | -46.35% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $715.37 | -27.31% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $31.76 | -18.14% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $160 | $192.97 | -17.09% | 15 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $12.92 | +31.58% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $4.92 | +265.85% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $4.38 | +128.31% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.60 | +337.50% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $5.20
Upside: +380.77%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $13.41
Upside: -17.97%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $19.16
Upside: +25.26%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $12.86
Upside: -30.02%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $169.41
Upside: +18.06%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $24.53
Upside: -22.54%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $71.14
Upside: -15.66%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $124.65
Upside: +95.75%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $8.76
Upside: +173.97%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $41.01
Upside: -46.35%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $715.37
Upside: -27.31%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $31.76
Upside: -18.14%
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $192.97
Upside: -17.09%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $12.92
Upside: +31.58%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $4.92
Upside: +265.85%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $4.38
Upside: +128.31%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.60
Upside: +337.50%